Increasing access to life-saving snakebite treatments.
The SRPNTS consortium aims to address this major public health gap by applying new tools and technologies to discover and develop a set of monoclonal antibodies with broad applicability to treat snakebite regardless of snake species around the globe.
The team aims to develop a product for broad global use regardless of snake species and believe that increasing the market size for the product will generate enough demand to ensure sustainable supply. The consortium brings together global partners to reduce morbidity and mortality from snakebite in Africa and India by developing the next-generation snakebite therapies that are effective, safe, affordable, and accessible.
The consortium’s work is funded through a grant from the UK Department for International Development (DFID).
The SRPNTS consortium (funded by the UK government the Foreign, Commonwealth, and Development Office) was formed in 2018 to develop new snakebite therapies using antibody technology originally developed in pursuit of more effective HIV treatment. This group of six institutions from five countries all have one goal: to stop snakebite by creating safer and more effective, affordable, accessible snakebite therapies. Join Professor Robert Harrison as he introduces the consortium.
SRPNTS: an introduction by Professor Robert Harrison.
The Scientific Research Partnership for Neglected Tropical Snakebite (SRPNTS) seeks to reduce morbidity and mortality from snakebite in Africa and India by delivering the next generation snakebite therapies that are effective, safe, affordable, and accessible to communities who need them most.